A qualitative study of healthcare provider awareness and informational needs regarding the nine-valent HPV vaccine

Monica L. Kasting, Shannon Wilson, Brian E. Dixon, Stephen M. Downs, Amit Kulkarni, Gregory D. Zimet

Research output: Contribution to journalArticle

6 Scopus citations


The 9-valent Human Papillomavirus (HPV) vaccine, 9vHPV, was licensed in the U.S. in December, 2014. We assessed healthcare provider (HCP) awareness of the newly approved vaccine and identified questions HCPs have about the vaccine. As part of a larger study, we used semi-structured interviews to ask 22 pediatric HCPs about their awareness of 9vHPV, questions they have about the vaccine, and questions they anticipate from patients and parents. Interviews were audio-recorded and transcribed then analyzed using inductive content analysis. Over half were aware of the vaccine but few HCPs claimed to be familiar with it. HCPs indicated several questions with common themes pertaining to efficacy, side effects, and cost. Only half of HCPs believed patients or parents would have questions. The results suggest strategies and areas for health systems and public health organizations to target in order to resolve unmet educational needs among HCPs regarding 9vHPV.

Original languageEnglish (US)
Pages (from-to)1331-1334
Number of pages4
Issue number11
StatePublished - Mar 8 2016



  • Awareness
  • Education
  • HPV
  • Healthcare provider
  • Sexually transmitted infection
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this